At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Johan Vansteenkiste, MD, PhD, from University of Leuven, Leuven, Belgium, discusses subgroup analyses and patient-reported outcomes from CheckMate 057, a phase 3, randomised clinical trial that was designed to compare nivolumab, an anti–PD-1 antibody, with docetaxel for the treatment of patients with advanced non-squamous non-small cell lung cancer.
Update from CheckMate 057: Nivolumab versus docetaxel in advanced non-squamous NSCLC
5th February 2016
Join our mailing list
To receive the EMJ updates straight to your inbox free of charge, please click the button below.Join Now